AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,376.00p
   
  • Change Today:
    -224.00p
  • 52 Week High: 12,696.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.26m
  • Volume: 1,715,496
  • Market Cap: £191,860m
  • RiskGrade: 123

AstraZeneca agrees to acquire TeneoTwo

By Iain Gilbert

Date: Tuesday 05 Jul 2022

LONDON (ShareCast) - (Sharecast News) - Drugmaker AstraZeneca has agreed to acquire TeneoTwo and its clinical-stage T-cell engager in a deal worth up to $1.26bn as part of an effort to accelerate the development of the potential new medicine for B-cell haematologic malignancies.
AstraZeneca will pay $100.0m for TeneoTwo and its TNB-486 T-cell engager, while additional contingent research and development-related milestone payments of up to $805.0m and further commercial-related milestone payments of up to $360.0m will also be due to TeneoTwo's equity holders.

The FTSE 100-listed group stated the transaction will be accounted for as an "intangible asset acquisition" and highlighted that the acquisition was expected to close in the third quarter, subject to customary closing conditions and regulatory clearances.

AZN also noted that the transaction did not impact its financial guidance for 2022.



Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,376.00p
Change Today -224.00p
% Change -1.78 %
52 Week High 12,696.00p
52 Week Low 9,501.00p
Volume 1,715,496
Shares Issued 1,550.26m
Market Cap £191,860m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.62% below the market average92.62% below the market average92.62% below the market average92.62% below the market average92.62% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
70.38% above the market average70.38% above the market average70.38% above the market average70.38% above the market average70.38% above the market average
88.68% above the sector average88.68% above the sector average88.68% above the sector average88.68% above the sector average88.68% above the sector average
Income
92.94% below the market average92.94% below the market average92.94% below the market average92.94% below the market average92.94% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.70% above the market average82.70% above the market average82.70% above the market average82.70% above the market average82.70% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 9
Buy 16
Neutral 5
Sell 0
Strong Sell 1
Total 31
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 11-Jun-2024

Time Volume / Share Price
17:26 1,169 @ 12,377.96p
17:26 47 @ 12,377.64p
17:26 579 @ 12,377.91p
17:26 66,685 @ 12,377.97p
17:26 15,155 @ 12,377.97p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page